Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Black men or women 18 years or older
History of recurrent genital herpes with at least 4 recurrences in preceding 12 months or in preceding 12 months prior to using suppressive antiviral therapy
Documented herpes simplex virus type 2 (HSV-2) seropositivity
Willingness to discontinue suppressive therapy during study, if applicable
Willingness and ability to comply with the study protocol
You may not be if
Pregnant or breastfeeding women
Women of childbearing potential not using accepted methods of contraception
Hypersensitivity to famciclovir or drugs with similar chemical structures
Renal dysfunction
Known or suspected to have decompensated liver disease
Known to have gastrointestinal malabsorption
Known to be immunocompromised
Known to be hypersensitive to ingredients in study medication
Clareo Health | Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
